Duobrii in Combination With Biologics

• Status: Recruiting
• Trial end date: 2020-09-01
• Target enrollment: 0
• Participant gender: All

Summary

12 weeks DUOBRII to patients with 2%-10% BSA who are receiving biologic therapy for at least 24 weeks

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Psoriasis Treatment Center of Central New Jersey
• Collaborator: Ortho Dermatologics

Criteria

Inclusion Criteria:

1. Male or female adult ≥ 18 years of age;

2. Diagnosis of chronic plaque-type

3. Psoriasis affecting 2%-10% BSA

4. Patient is being treated with biologic therapy for a minimum of 24 weeks

5. Able and willing to give written informed consent prior to performance of any study-related procedures

Exclusion Criteria:

1. Psoriasis affecting ˂2% or >10% BSA

2. Patient not receiving a biologic agent, or receiving biologic agent <24weeks

3. Received treatment with any topical antipsoriatic drug product within 14 days prior to the Baseline visit.

4. Has previously used DUOBRII